Galangin cooperates with oxaliplatin to inhibit the proliferation and invasion of colorectal cancer cells by targeting CBX3

Abstract

Abstract Objective Examining the potential mechanism underlying the effect of galangin combined with oxaliplatin on the invasion and proliferation of colorectal cancer. Methods The effects of galangin combined with oxaliplatin on colorectal cancer (CRC) cell invasion and proliferation were assessed using CCK8 and Transwell assays. Using WB and qPCR, the expression of CBX3 in several CRC cell lines was identified. The levels of CBX3 in normal colorectal tissues and CRC tissues were compared using HPA and GEPIA, and the impact of CBX3 on the prognosis of CRC patients was investigated using GEPIA. To determine whether galangin targets CBX3 to influence the growth and invasion of CRC cells, cell assays were employed. The levels of ROS in HCT116 were measured by immunofluorescence following galangin treatment. The impact of CBX3 on immune cell infiltration in CRC was examined using TIMER. GEPIA produced a list of CBX3-related genes, and R was utilized to perform GO/KEGG enrichment analysis. Results We found that galangin combined with oxaliplatin inhibited the proliferation and invasion of CRC cells and down-regulated the expression of CBX3, which was rescued by overexpression of CBX3. DFS was shorter in those with elevated CBX3 expression. The level of ROS in HCT116 was significantly increased after galangin treatment. The invasion of CD8 + T cells and macrophages in the immunological microenvironment of CRC is favorably linked with increased expression of CBX3. Nuclear chromatin, histone binding, and covalent chromatin modification are enriched regions in CBX3 and related genes. Conclusion Galangin combine with oxaliplatin can inhibit the proliferation and invasion of colorectal cancer cells by down-regulating the expression of CBX3, and CBX3 is highly expressed in colorectal cancer and is related to short DFS.